I-SQUARED-CAPITAL
9.12.2020 17:02:08 CET | Business Wire | Press release
I Squared Capital, through its ISQ Global Infrastructure Fund II, has acquired and combined Infofabrica Holdings Pte Ltd and Cloud Kinetics Tech Pte Ltd, two Cloud migration services companies based in Singapore. The combined businesses are poised to become a leading Cloud migration and managed services provider in Southeast Asia and India, providing capability across all major public Cloud operators. These investments are part of a new Asian Digital Infrastructure platform and will enable I Squared Capital’s Digital Infrastructure companies to offer comprehensive Cloud-based solutions to their customers. The Cloud platform will have a growing pool of over 300 professionals with deep experience in Cloud infrastructure, data, analytics, application modernization and Cloud management and possess a broad range of Cloud certifications.
“The future of data and computing will be driven by the corporate adoption of hybrid Cloud solutions through an orchestrated mix of on-premises infrastructure, co-location and Cloud services. Offering seamless and efficient migration to the hybrid Cloud relieves a critical bottleneck to Cloud adoption, especially in the Asia-Pacific region. The combination of Infofabrica and Cloud Kinetics will result in a powerful Cloud migration solution provider for our clients,” said Gautam Bhandari, Managing Partner of I Squared Capital. “With these acquisitions, our global investments and commitments to the Digital Infrastructure sector are over $2.6 billion and growing.”
Cloud migration consists of the specialized capabilities and technologies, undertaken by certified experts, to enable businesses to move to and operate on the Cloud seamlessly. IDC predicts that Southeast Asia’s Cloud computing market will reach $40 billion by 2025, underscoring its importance in our daily lives. The platform is co-founded and being led by Haji Munshi, a technology executive who has held senior leadership positions at Google Cloud, Cisco, Hewlett Packard Enterprise and Dell, and Tameem Ebrahim, ex-Founding Partner of Quvat Capital and was an investment banker at Merrill Lynch and Deutsche Bank in Southeast Asia.
“The debate on the need for Cloud has ended after the experience of the Covid-19 pandemic,” said Haji Munshi, Group CEO of InfoFabrica and Cloud Kinetics. “Whether businesses are developing and testing their new applications, scaling their online e-commerce offerings, or running their core business workloads, this is possible only because of the stable, scalable solutions offered by the public Cloud. The demand for technical capability to migrate to Cloud has far outstripped supply in Asia-Pacific thus far and the combined company will be a market leader in Cloud migration services.”
“We are really pleased to be partnering with I Squared Capital, their expertise and breadth in Asia, along with existing large-scale investments in telecoms and data centers, will certainly accelerate and move us closer to our vision to be the top cloud migration and managed services provider in the region,” commented Abu Bakar Mohd Nor, Chairman of IFF. “The complementary capabilities of InfoFabrica and Cloud Kinetics is key and part of our strategy to be an end-to-end Cloud specialist and also simplify our clients’ Cloud migration journey.”
About Infofabrica Holdings (https://www.infofabrica.com/ ): Founded in 2013, InfoFabrica Holdings Pte Ltd has operations in Singapore, Indonesia, Vietnam and Malaysia. InfoFabrica is a certified Cloud partner of Amazon Web Services, Google Cloud, IBM Cloud.
About Cloud Kinetics (https://www.Cloud-kinetics.com/ ): Founded in 2012, Cloud Kinetics Tech Pte Ltd has operations in Singapore, Thailand, India and the United States. Cloud Kinetics is a certified Cloud partner of Microsoft Azure, Amazon Web Services and Google Cloud.
About I Squared Capital (http://www.isquaredcapital.com/ ): I Squared Capital is an independent global infrastructure investment manager focusing on energy, utilities, digital infrastructure, transport and social infrastructure in the Americas, Europe and Asia. The firm has offices in Miami Hong Kong, London, New Delhi, New York, and Singapore.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201209005751/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom